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Background:  Accurate  risk  stratification  is  an  important  step  in  the  initial  management  of  acute
coronary syndrome  (ACS),  and  current  guidelines  recommend  the  use  of  risk  scores,  such  as  the
Global Registry  of  Acute  Coronary  Events  risk  score  (GRACE  RS).  Recent  studies  have  suggested
that abdominal  obesity  is  associated  with  cardiovascular  events  in  patients  with  ACS.  However,
little is  known  about  the  additional  value  of  abdominal  obesity  beyond  risk  scores.  The  aim  of
our study  was  thus  to  assess  whether  waist  circumference,  a  surrogate  of  abdominal  adiposity,
adds prognostic  information  to  the  GRACE  RS.
Methods:  This  was  a  retrospective  cohort  study  of  ACS  patients  admitted  consecutively  to  a
cardiac care  unit  between  June  2009  and  July  2010.  The  composite  of  all-cause  mortality  or
myocardial  reinfarction  within  six  months  of  index  hospitalization  was  used  as  the  endpoint  for
the analysis.
Results:  A  total  of  285  patients  were  studied,  96.1%  admitted  for  myocardial  infarction  (with
or without  ST  elevation)  and  3.9%  for  unstable  angina.  At  the  end  of  the  follow-up  period,  10
patients had  died  and  the  composite  endpoint  had  been  reached  in  27  patients  (9.5%).  More  than
70% of  the  study  population  were  obese  or  overweight,  and  abdominal  obesity  was  present  in
44.6%. The  GRACE  RS  showed  poor  predictive  accuracy  (area  under  the  curve  0.60),  and  most  of
the GRACE  variables  did  not  reach  statistical  significance  in  multivariate  analysis.  The  addition
of waist  circumference  to  the  GRACE  RS  did  not  improve  its  discriminatory  performance.
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Avaliação  do  risco;
Score  de  risco  GRACE;
Síndroma  coronária
aguda
O  papel  da  obesidade  central  na  estratificação de  risco  após  um  evento  coronário
agudo:  a  obesidade  central  adiciona  valor  prognóstico  à  pontuação  de  risco  do  Registo
Global  de  Eventos  Coronários  Agudos  em  doentes  com  Síndrome  Coronária  Aguda?
Resumo
Introdução:  A  estratificação  do  risco  é  um  aspeto  fundamental  da  abordagem  inicial  em  doentes
com síndrome  coronária  aguda  (SCA)  e  atualmente  as  normas  de  orientação  clínica  recomen-
dam o  uso  de  modelos  de  risco,  como  o  Global  Registry  of  Acute  Coronary  Events  Risk  Score
(GRACE-RS).  Estudos  recentes  sugerem  que  a  obesidade  abdominal  está  associada  com  eventos
cardiovasculares  em  doentes  com  ACS.  Contudo,  pouco  é  conhecido  sobre  valor  adicional  da
obesidade  abdominal  comparativamente  com  um  modelo  de  risco.  Consequentemente,  o  obje-
tivo do  estudo  foi  avaliar  se  o  perímetro  abdominal,  um  marcador  da  adiposidade  abdominal,
acrescenta  informação  ao  GRACE-RS.
Métodos:  Estudo  de  coorte  retrospetivo  de  doentes  admitidos  de  forma  consecutiva  com  SCA
num hospital  português,  entre  junho  de  2009  e  julho  de  2010.  A  ocorrência  de  morte  ou  re-
enfarte do  miocárdio  no  período  de  seis  meses  foi  utilizada  como  endpoint.
Resultados:  Foram  estudados  285  doentes,  96,1%  com  enfarte  do  miocárdio  (com  ou  sem
elevação do  segmento-ST)  e  3,9%  com  angina  instável.  No  final  do  follow-up,  10  doentes  mor-
reram e  o  endpoint  foi  atingido  em  27  (9,5%)  dos  doentes.  Mais  de  70%  da  população  era  obesa
ou apresentava  excesso  de  peso,  e  44,6%  apresentavam  obesidade  abdominal.  O  GRACE-RS
apresentou  um  baixo  poder  discriminatório  (AUC  =  0,60),  sendo  que  na  análise  multivariada  a
maioria das  variáveis  GRACE  não  atingiu  a  significância  estatística.  A  introdução  do  perímetro
abdominal  no  GRACE-RS  não  melhorou  o  seu  poder  discriminatório.
Conclusão:  A  medição  da  obesidade  abdominal  não  acrescenta  informação  prognóstica  ao
GRACE-RS  preditor  da  morte  ou  re-enfarte  aos  seis  meses  de  seguimento  clínico.
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cute  coronary  syndrome  (ACS)  is  the  leading  cause  of
eath  in  industrialized  countries  and  is  thus  a  major  health
roblem.1,2
Obesity  is  a  growing  epidemic  and  a  global  healthcare
hallenge.3,4 It  is  associated  with  cardiovascular  mortal-
ty  and  with  advanced  coronary  artery  disease  (CAD).3--6
owever,  obesity  is  heterogeneous  in  terms  of  metabolic
rofile  and  risk  implications.7 In  this  regard,  abdominal  obe-
ity  is  increasingly  recognized  as  an  important  risk  factor
or  cardiovascular  disease  as  well  as  a  major  correlate  of
therogenic  and  metabolic  abnormalities.7--10 Visceral  fat
ccumulation  is  a  better  marker  of  the  cardiometabolic  risk
ssociated  with  obesity  than  body  mass  index  (BMI).8,11 Adi-
ose  tissue  is  known  to  be  an  active  endocrine  organ.  Due
o  its  metabolic  activity  and  anatomic  location,  abdominal
at  secretes  large  quantities  of  adipokines  and  inflammatory
ytokines  directly  into  the  portal  circulation  that  contribute
o  the  proinflammatory  and  prothrombotic  state  of  visceral
besity,  which  may  be  responsible  for  the  higher  attributed
isk  in  abdominally  obese  subjects.9 Moreover,  abdominal
besity  is  the  most  prevalent  feature  of  the  metabolic  syn-
rome,  which  is  predictive  of  cardiovascular  mortality.12--14
etabolic  syndrome  is  highly  prevalent  in  ACS  patients,
nd  therefore  the  associated  cardiometabolic  risk  should  be
ssessed  in  this  population.
Direct  measures  of  abdominal  obesity,  such  as  waist  cir-
umference  (WC),  might  help  to  better  assess  fat  location





t  the  population  level,  increased  WC  has  been  indepen-
ently  related  to  all-cause  mortality,  myocardial  infarction
MI)  and  CAD  risk.16 Although  the  link  between  abdominal
dipose  depot  and  mortality  has  been  extensively  demon-
trated  in  the  general  population,  this  relationship  appears
ore  complex  in  ACS  patients  and  requires  further  clarifi-
ation.  Despite  the  prevalence  of  abdominal  obesity,  few
tudies  have  addressed  its  impact  on  prognosis  after  ACS.
ecent  evidence  has  demonstrated  that  elevated  WC  is  asso-
iated  with  increased  mortality  in  patients  with  CAD.3 It  may
hus  be  hypothesized  that  assessment  of  WC  could  improve
isk  prediction  in  ACS  patients.  However,  to  be  a  useful  tool
o  predict  risk  in  ACS,  it  has  to  demonstrate  incremental
tility  beyond  that  of  an  established  risk  model.17
Clinical  management  of  ACS  patients  should  be  guided  by
 risk  estimate.18,19 ACS  covers  a  large  spectrum  of  clinical
onditions  and  for  this  reason  patients  are  heterogeneous
n  terms  of  risk  profile  for  recurrent  events.  Risk  stratifi-
ation  enables  tailoring  of  aggressive  medical  therapies  or
nvasive  procedures  towards  higher-risk  individuals.20,21 Evi-
ence  and  current  guidelines  suggest  that  the  benefit  of
ore  intensive  treatment  is  related  to  individual  patients’
isk  of  clinical  events.22
To  optimize  risk  assessment,  several  prognostic  factors
ust  be  simultaneously  taken  into  account.  Risk  scores  are
ritical  for  this  purpose.  Several  risk  scores  developed  in  the
ast  decade  are  currently  available  to  help  clinicians  with
isk  stratification.  Of  those,  the  Global  Registry  of  Acute
oronary  Events  (GRACE)  risk  score  (GRACE  RS)  is  proba-
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The  GRACE  RS  can  be  used  to  estimate  the  risk  of  mortal-
ity  or  the  combined  risk  of  mortality  or  MI  at  admission  or
at  six  months.  Although  the  GRACE  RS  has  been  extensively
evaluated  and  validated  in  ACS  patients,  accurate  risk  strat-
ification  is  a  difficult  and  complex  task.  Little  is  known  about
the  additional  value  of  abdominal  obesity  for  risk  strati-
fication  beyond  other  prognostic  variables  already  used  in
practice.23 The  purpose  of  the  present  study  was  to  assess
the  incremental  prognostic  value  of  WC  beyond  the  GRACE
RS  in  a  cohort  of  consecutive  patients  admitted  to  a  cardiac
care  unit  (CCU)  with  a  diagnosis  of  ACS.
Methods
Study  population
The  present  study  is  a  retrospective  cohort  study  involving
464  patients  consecutively  admitted  for  ACS  in  a  CCU  of  a
Portuguese  university  hospital  between  June  2009  and  July
2010.
Study  protocol  and  data  collection
Baseline  characteristics  were  collected  prospectively  by
department  clinicians  in  an  internal  database.  The  GRACE  RS
predicting  six-month  mortality  or  MI  from  hospital  admission
was  retrospectively  calculated  for  each  patient  using  the
web  calculator  (available  at  http://umassed.org/grace/).
Patients  without  recorded  WC  measurement,  those  for
whom  not  all  prognostic  data  required  for  the  GRACE
RS  calculation  was  available,  and  those  without  complete
follow-up  at  six  months  from  admission,  were  excluded.  The
final  study  population  thus  included  285  individuals.  Some
data  on  the  variables  studied  were  missing.  The  study  pro-
tocol  was  approved  by  the  institution’s  ethics  committee.
Definitions  of  variables  of  interest
The  WC  measures  were  performed  using  a  stretch-resistant
tape  at  the  midpoint  between  the  iliac  crest  and  the
lower  costal  arch.  For  practical  purposes,  increased  WC
was  defined  according  to  the  clinical  standard  cutoffs  of
the  National  Cholesterol  Education  Program  Adult  Treatment
Panel  III  (NCEP  ATP  III)  of  >  88  cm  for  women  and  >  102  cm
for  men.
Elevated  cardiac  enzymes  were  defined  as  CK-MB  more
than  double  the  upper  limit  of  the  hospital’s  normal  ranges
or  as  positive  troponin  I.  ST-segment  deviation  was  defined
as  ST-segment  elevation  or  depression  ≥1  mV,  seen  in  any
location  on  the  admission  ECG.  Killip  class  was  recorded
at  hospital  admission.  All  admission  laboratory  tests  were
collected  within  24  hours  of  clinical  presentation.
Patients  received  evidence-based  medication  and  under-
went  cardiac  procedures  in  a  nonrandomized  manner
according  to  the  physician’s  criteria  and  local  routines.
Standard  definitions  for  in-hospital  complications  and  out-
comes  were  used.  Standard  pharmacological  treatments  in
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tudy  endpoint
he  study  endpoint  was  defined  as  the  composite  of  all-
ause  mortality  or  hospitalization  for  MI  within  six  months
f  the  index  diagnosis.  Follow-up  information  was  collected
y  telephone  contacts.  Medical  records  were  reviewed  to
dentify  or  confirm  clinical  events.
tatistical  analysis
ontinuous  variables  are  presented  as  means  (standard
eviation)  or  as  medians  (interquartile  range).  Categorical
ariables  are  expressed  as  frequencies  (percentage).  Pear-
on’s  chi-square  test  or  Fisher’s  exact  test  were  used  to
ompare  proportions  of  categorical  variables.  The  Student’s
 test  or  the  Mann--Whitney  U  test  was  used,  as  appropriate,
o  compare  differences  in  continuous  variables.
To  assess  the  additional  value  of  WC  beyond  the  GRACE
S,  the  following  procedures  were  applied:  (A)  individual
ariables  of  the  GRACE  RS  alone  (model  1)  or  associated
ith  WC  (model  2)  were  entered  as  covariates  in  binary
egression  analysis;  (B)  the  predicted  probabilities  for  each
odel  were  obtained;  (C)  these  probabilities  were  used  to
onstruct  receiver  operating  characteristic  (ROC)  curves  and
he  area  under  the  curve  (AUC)  for  each  model  was  calcu-
ated  to  assess  discrimination;  (D)  finally,  the  two  AUCs  were
ompared  using  the  method  proposed  by  Hanley  and  McNeil.
The  GRACE  RS  was  dichotomized  according  to  the  best
utoff  point  on  the  ROC  curve.  The  dichotomized  GRACE  RS
as  related  to  the  endpoint  using  Pearson’s  chi-square  test.
The  statistical  analysis  was  performed  with  SPSS® 19.0
SPSS  Inc.,  Chicago,  Illinois)  and  with  MedCalc® 12.0.4.0
Mariakerke,  Belgium).  All  statistical  tests  were  two-sided,
nd  a  value  of  p  <  0.05  was  taken  as  statistically  significant.
esults
opulation  characteristics
 total  of  285  patients  were  studied.  Their  mean  age  was
3±13  years  and  78.9%  were  males;  57.5%  were  admitted
or  ST-segment  elevation  MI  (STEMI),  38.6%  for  non-STEMI
NSTEMI),  and  the  remainder  for  unstable  angina.  The
edian  time  from  symptom  onset  to  CCU  admission  was  7.0
103)  hours.
As  reported  in  Table  1,  the  majority  of  patients  had  sys-
emic  hypertension  and  dyslipidemia.  Diabetes  was  present
n  25.6%,  and  48.4%  reported  current  or  previous  smoking;
4.0%  had  previous  MI  and  17.2%  previous  angina.  Chronic
enal  failure  was  present  in  4.9%  of  patients.
Patients  with  the  defined  endpoint  were  older  (68.3  years
s.  62.3  years,  p=0.023),  presented  with  lower  glomeru-
ar  filtration  rate  (GFR)  (68.10  ml/min  vs.  93.74  ml/min,
=0.002),  higher  plasma  creatinine  (1.1  mg/dl  vs.  0.9  mg/dl,
=0.013),  significantly  higher  serum  C-reactive  protein
CRP)  (8.0  mg/dl  vs.  4.1  mg/dl,  p=0.022)  and  NT-pro-BNP
1575  pg/ml  vs.  1033  pg/ml,  p=0.049),  and  lower  admission
emoglobin  (13  g/dl  vs.  14  g/dl,  p=0.009).
Hospital  stay  was  relatively  uneventful,  with  3  (1.1%)
eported  deaths  and  12  (4.2%)  in-hospital  reinfarctions.
ean  hospital  stay  was  approximately  seven  days.
772  A.  Martins  et  al.
Table  1  Baseline  demographic  and  clinical  characteristics  of  the  study  population.
Variable  Total  population  No  events  Events  p
Age  (years)  62.9  (13.1)  62.3  (13)  68.3  (11.8)  0.023
Male 225  (78.9)  205  (79.5)  20  (74.1)  0.514
BMI (kg/m2) 27.6  (0.2) 27.6  (4.2) 27.2  (3.2) 0.568
Waist circumference  (cm)  27.6  (4.1)  98.5  (11)  98.7  (6.9)  0.926
High-risk WC  (ATP  III)  127  (44.6)  114  (44.2)  13  (48.1)  0.155
High-risk WC  (IDF)  207  (72.6)  185  (71.7)  22  (81.5)  0.278
Medical history
Systemic  hypertension  183  (64.2)  163  (63.2)  20  (74.1)  0.261
Diabetes 73  (25.6)  63  (24.4)  10  (37.0)  0.153
Dyslipidemia  155  (54.4)  137  (53.1)  18  (66.7)  0.178
Previous smoking 54  (18.9) 53  (20.5) 1  (3.7) 0.034
Current smoking  84  (29.5)  77  (29.8)  7  (25.9)  0.671
Previous angina  49  (17.2)  43  (16.7)  6  (22.2)  0.467
Previous MI  40  (14.0)  35  (13.6)  5  (18.5)  0.481
History of  chronic  renal  failure  14  (4.9)  7  (2.7)  3  (11.1)  0.058
Event classification
STEMI  164  (57.5)  152  (58.9)  12  (44.4)  0.284
NSTEMI 110  (38.6)  97  (37.6)  13  (48.1)  0.148
UA 11  (3.9)  9  (3.5)  2  (7.4)  0.288
Clinical presentation
Heart  rate  on  admission  (bpm)  75  (18)  75  (18)  77(22)  0.711
Systolic blood  pressure  (mmHg)  126  (24)  125  (24)  134  (27)  0.06
Diastolic blood  pressure  (mmHg)  77  (14)  77  (14)  74  (13)  0.444
Killip class  ≥  2  62  (21.8)  53  (20.5)  9  (33.3)  0.125
Preserved left  ventricular  function  139  (49.5)  125  (49.0)  14  (53.8)  0.639
Blood tests
Estimated  GFR  (ml/min/1.73  m2)  91.43  (38.68)  93.74  (39.69)  68.10  (31.8)  0.002
Creatinine (mg/dl)  (median/IQR)  0.9/5.2  0.9/5.2  1.1/3.5  0.013
Hemoglobin  (g/dl)  14  (1.8)  14  (1.7)  13  (2.2)  0.009
CK-MB (U/l) 167  (160)  171  (163)  130  (126)  0.202
NT-pro-BNP  (pg/ml)  (median/IQR)  1089/69  969  1033/69  969  1575/40  972  0.049
CRP (mg/l)  (median/IQR) 4.20/314.0  4.1/314.0  8.0/173.4  0.022
Peak cardiac  troponin  I  (ng/l)  (median/IQR) 2.66/68  2.63/68.0  2.99/22.73  0.875
Pre-hospital  delay  (hours)  (median/IQR) 2.2/88.4  2.0/88.4  4.6/32.1  0.015
Length of  hospital  stay  (days) 6.9  (3.4) 6.9  (3.8)  7.3  (3.4)  0.57
GRACE risk  score  for  six-month  mortality  or  reinfarction  173  (50)  171  (49)  184  (52)  0.218
Continuous variables are shown as mean and standard deviation, if not stated otherwise. Qualitative variables are presented as number




















More  than  70%  of  the  study  population  were  obese  or  over-
weight,  and  almost  one  third  were  obese  according  to  World
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ATP III: National Cholesterol Education Program Adult Treatment Pa
ST-elevation myocardial infarction; UA: unstable angina.
Further  demographic,  clinical  and  laboratory  data  are
hown  in  Table  1.
n-hospital  management  and  treatment
t discharge
n  general,  hospital  management  and  therapy  at  discharge
id  not  differ  between  patients  with  or  without  events,
lthough  higher  use  of  GP  IIb/IIIa  inhibitors  was  related  to
vent  occurrence.  As  shown  in  Table  2, 69.1%  of  patients
nderwent  coronary  revascularization;  percutaneous  coro-
ary  intervention  (PCI)  was  the  main  reperfusion  strategy.
he  overall  rate  of  discharge  therapy  in  accordance  with
nternational  guidelines  was  very  high.
H
A
riteria; IQR: interquartile range; MI: myocardial infarction; NCEP
I criteria; NSTEMI: non-ST-elevation myocardial infarction; STEMI:
rognostic  information
t  six  months  from  hospital  admission,  cumulative  mortality
as  3.5%  (10  patients),  and  there  had  been  20  reinfarctions
7.1%).  The  composite  endpoint  of  mortality  or  MI  was  thus
eached  in  27  patients  (9.5%).
eneral  and  abdominal  obesityealth  Organization  (WHO)  cutoffs.  High-risk  WC  (NCEP
TP  III  criteria)  was  present  in  44.6%,  and  the  proportion
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Table  2  In-hospital  management  and  treatment  at  discharge.
Variable  Total  population  No  events  Events  p
PCI  191  (67.3)  175  (68.1)  16  (59.3)  0.352
Rescue PCI  5  (1.8)  4  (1.6)  1  (3.7)  0.395
Fibrinolysis 5  (1.8)  5  (1.9)  0  (0)  --
No revascularization  83  (29.2)  73  (28.4)  10  (37.0)  0.348
Use of  anticoagulants  269  (94.7)  245  (94.7)  24  (92.3)  0.636
Use of  GP  IIb/IIIa  inhibitors  48  (16.9)  40  (15.5)  8  (30.8)  0.048
Discharge medications
Beta  blocker 264  (93) 240  (93)  26  (100)  0.703
ACEi 284  (100) 230  (89.1) 26  (100) 1.00
Aspirin 284  (100) 258  (100) 26  (100) --
Clopidogrel  280  (98.6) 255  (98.8) 26  (100) 0.32
Statin 284  (100)  255  (98.8)  26  (100)  1.00
Nitrates 104  (36.7)  89  (34.6)  26  (100)  0.02
t. ACEi: angiotensin-converting enzyme inhibitor; PCI: percutaneous
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increased  to  72.6%  when  the  International  Diabetes  Federa-
tion  (IDF)  criteria  were  used.5,24
GRACE  risk  score  performance  and  additional
prognostic  value  of  abdominal  obesity
In  the  multivariate  model  for  individual  variables  from  the
GRACE  RS  (model  1),  only  ST-segment  deviation  was  an  inde-
pendent  predictor  of  the  endpoint  (odds  ratio  [OR]=3.56,
p=0.038).  Elevated  cardiac  enzymes  showed  a  significant
protective  effect  for  event  occurrence  (OR=0.20,  p=0.013).
The  remaining  covariates  did  not  reach  statistical  signifi-
cance  (Table  3).  Model  2  revealed  similar  results;  WC  was
found  not  to  be  an  independent  predictor  of  outcome  in
multivariate  analysis  (p=0.692).  The  ROC  curves  for  each
multivariate  model  and  for  the  GRACE  RS  are  illustrated
in  Figure  1,  and  the  AUCs  and  other  predictive  measures
are  presented  in  Table  4.  The  inclusion  of  WC  in  the  GRACE
RS-based  model  did  not  improve  its  discriminatory  perfor-
mance.  There  were  no  differences  between  the  AUCs  of
the  two  models  according  to  Hanley  and  McNeil’s  method.





Table  3  Binary  logistic  regression  for  predicting  six-month  mort
waist circumference.
OR  
Age  (10  year  increments)  1.40
Creatinine (0.40  mg/ml  increments)  1.00
Systolic blood  pressure  (20  mmHg  decrements)  1.02
Heart rate  (20  bpm  decrements)  1.24
Killip class  1.48
Cardiac arrest  at  admission  0.26
ST-segment  deviation  3.56
Elevated cardiac  enzymes  0.20
Waist circumference  --  1.00.80.60.2 0.40.0
Figure  1  ROC  curves.
AUC=0.60):  the  point  for  best  accuracy  on  the  ROC  curve  for
he  GRACE  RS  was  165.  After  stratification  by  the  best  cut-
ff  value,  we  found  a  significant  association  between  high
RACE  RS  and  the  endpoint  (p=0.026).
ality  or  MI  using  GRACE  predictors  alone  and  combined  with
Model  1  Model  2
p  OR  p
 0.060  1.40  0.062
 0.139  1.00  0.131
 0.124  1.06  0.114
 0.652  1.25  0.707
 0.290  1.50  0.279
 0.265  0.26  0.261
 0.038  3.56  0.037
 0.013  0.20  0.014
--  0.99  0.692
774  
Table  4  Predictive  accuracy.
AUC  p  95%  CI
Model  1 0.757 <0.001  0.658--0.856
Model 2  0.759  <0.001  0.662--0.856
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iscussion
he  present  study  set  out  to  assess  whether  the  inclusion  of
C  measurement  in  the  multivariate  model  derived  from  the
RACE  RS  improved  risk  prediction  in  ACS  patients.  To  the
est  of  our  knowledge,  this  is  the  first  study  to  quantify  the
dditional  predictive  value  of  WC  in  relation  to  the  GRACE
S.
Our  data  demonstrated  that  WC  assessment  did  not
mprove  the  predictive  accuracy  of  the  GRACE  RS.  Further-
ore,  this  analysis  did  not  confirm  WC  measurement  as  an
ndependent  outcome  predictor  in  multivariate  analysis.  An
dditional  unanticipated  result  was  that  the  predictive  per-
ormance  of  the  calculated  GRACE  RS  was  shown  to  be  poor.
The  study  population  was  mostly  composed  of  males
78.9%);  similar  proportions  were  reported  in  previous  stud-
es  of  ACS  populations.  Mean  age  and  previous  medical
onditions  were  similar  to  those  of  the  GRACE  cohort.16 A
igher  proportion  of  STEMI  patients  was  observed  (57.5%),
ompared  to  ACS  registries.18,21 However,  our  cardiac  center
eceives  patients  from  peripheral  hospitals  unable  to  per-
orm  PCI,  which  might  explain  the  number  of  STEMI  patients
bserved  for  whom  immediate  revascularization  procedures
ere  required.25
The  results  revealed  that  higher  CRP  and  NT-pro-BNP  and
ower  hemoglobin  level  at  admission  and  lower  GFR  were
elated  to  outcome.  All  of  these  biomarkers  are  considered
stablished  prognostic  markers,  although  none  are  currently
sed  in  risk  scores.26
Aggressive  treatment  of  ACS  has  become  widespread,  as
hown  by  the  PCI  rate  in  our  study  (67.3%).  Six-month  mor-
ality  was  3.5%,  lower  that  observed  in  GRACE  or  in  the
ontemporary  MASCARA  registry.21 Nevertheless,  unlike  the
resent  analysis,  both  registries  had  a  PCI  rate  lower  than
5%,  which  may  explain  our  lower  mortality.  Besides,  overall
vidence-based  cardiovascular  therapy  rates  were  very  high,
hich  has  been  associated  with  improvements  in  outcome.25
The  prevalence  of  general  and  abdominal  obesity  was
ery  high  in  the  present  analysis  (26.9%  and  44.6%,  respec-
ively),  highlighting  the  obesity  epidemic.  These  results
onfirm  those  of  studies  addressing  the  impact  of  obesity
n  ACS  prognosis.3,4,12 It  is  recognized  that  abdominal  obe-
ity  correlates  with  excessive  visceral  adiposity,  which  is
ssociated  with  several  proatherogenic  features,  includ-
ng  insulin  resistance,  hypertriglyceridemia,  diabetes  and
ypertension.3 Despite  the  unquestionable  utility  of  BMI  at
he  population  level,  it  appears  to  be  a  poor  marker  of
diposity-related  risk  in  ACS,  and  there  is  currently  a  debate
s  to  whether  an  ‘‘obesity  paradox’’  exists  in  ACS.27 The
ssociation  of  adipose  tissue  with  mortality  in  ACS  is  com-
lex,  and  may  rely  more  on  the  location  than  on  the  total
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In  a  recent  meta-analysis,  Coutinho  et  al.  demonstrated
hat  in  CAD  patients,  increasing  abdominal  obesity  (repre-
ented  by  WC  or  waist-to-hip  ratio  [WHR])  was  associated
ith  high  mortality,  independently  of  BMI,3 while  Lee  et  al.
ound  that  WHR  was  an  independent  predictor  of  six-month
ortality  in  STEMI  patients.11 However,  our  results  did  not
upport  the  prognostic  value  of  abdominal  obesity  in  ACS.
eller  et  al.  also  concluded  that  neither  BMI  nor  WC  inde-
endently  predicted  mortality  after  acute  MI.  However,  they
bserved  that  patients  with  high  WC  but  normal  BMI  (sup-
osedly  reflecting  the  presence  of  visceral  adiposity)  had  a
oorer  prognosis.12 Similar  results  were  reported  by  Kadakia
t  al.4
We  decided  to  use  a  combined  approach,  using  the  GRACE
S  as  a  prognostic  reference.  However,  our  data  demon-
trated  that  the  GRACE  RS  had  unexpectedly  poor  predictive
ccuracy,  meaning  that  it  represents  a  random  classification
f  the  risk  of  event  occurrence.  Despite  its  broad  accep-
ance,  it  should  be  recognized  that  the  use  of  the  GRACE
S  in  different  populations  from  its  original  cohort  may
ompromise  its  accuracy.  Besides,  Beygui  et  al.  stated  that
he  discriminatory  value  of  the  GRACE  RS  might  be  limited  in
 low-event  population.28 Although  the  GRACE  RS  has  been
alidated  in  a Portuguese  cohort  of  NSTEMI  patients  by  De
raújo  Gonçalves  et  al.,  these  authors  studied  different  time
oints  and  used  a  more  selected  population.22
Most  of  the  GRACE  RS  variables  did  not  reach  statistical
ignificance  in  multivariate  analysis.  However,  ST-segment
eviation  was  shown  to  be  an  independent  predictor  of  out-
ome.  This  feature  is  actually  a  powerful  risk  predictor  and
as  been  incorporated  in  several  risk  scores.  Yan  et  al.
ound  that  continuous  ST-segment  monitoring  in  NSTEMI
atients  confers  additional  prognostic  value  beyond  the
RACE  RS.29 However,  Fox  et  al.  stated  that  although  the
CG  is  helpful  for  guiding  treatment,  it  is  unable  to  predict
ate  complications,  and  a  multivariate  approach  is  therefore
eeded.2 Nevertheless,  almost  all  the  predictive  informa-
ion  associated  with  the  GRACE  RS  in  the  study  population
as  due  to  ST  changes,  which  raises  doubts  concerning
he  usefulness  of  the  GRACE  RS  in  clinical  practice.  More-
ver,  elevated  cardiac  enzymes  had  a  significant  protective
rognostic  effect.  The  mechanism  behind  this  relation  to
utcome  cannot  be  ascertained,  since  any  measurable  car-
iac  troponin  is  related  to  an  unfavorable  prognosis  and  even
inor  CK-MB  enzyme  elevations  appear  to  have  prognostic
mplications.17 Nevertheless,  it  should  be  pointed  that  90.2%
f  our  study  population  had  elevated  cardiac  enzymes,  and
herefore  the  statistical  analysis  could  have  been  skewed.
AUC  is  a  commonly  used  statistic.  However,  it  simply  and
irectly  addresses  discriminatory  ability,  a  major  but  not
nique  component  of  accuracy.  Recent  and  more  refined  sta-
istical  methods,  such  as  net  reclassification  improvement
nd  integrated  discrimination  improvement,  have  been  pro-
osed  as  better  tools  for  assessment  of  the  additional  value
f  a  risk  marker.30
imitations and future perspectiveshe  study  has  several  limitations,  and  consequently  its
esults  should  be  interpreted  with  caution.  Abdominal  obe-
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prognosis  of  these  individuals  was  poorer  (with  higher  mor-
tality),  although  their  general  baseline  characteristics  did
not  differ  from  those  of  the  study  population.  Severe  clini-
cal  status  might  have  limited  anthropometric  measurement
in  several  individuals  and  therefore  a  selection  bias  cannot
be  excluded.
Second,  this  was  a  relatively  small  retrospective  anal-
ysis  in  a  single  institution,  based  on  nonrandomized  data.
Accordingly,  the  negative  results  obtained  could  be  due  to
insufficient  statistical  power,  and  therefore  this  issue  should
be  revisited  in  larger  population-based  multicenter  stud-
ies,  perhaps  with  extended  follow-up,  to  assess  the  delayed
prognostic  impact  of  abdominal  obesity.
Our  results  should  be  considered  exploratory  and  need  to
be  confirmed  by  future  studies.
Conclusion
Routine  early  risk  stratification  remains  an  essential  part
of  ACS  care,  and  is  supported  by  risk  scores,  such  as  the
GRACE  RS.  However,  risk  scores  need  to  be  continually
re-evaluated,  since  accurate  risk  stratification  is  still  a  chal-
lenge.  In  this  study,  abdominal  obesity  did  not  improve  the
discriminatory  ability  of  the  GRACE  RS,  and  we  can  there-
fore  conclude  that  abdominal  obesity  assessment  does  not
increase  the  prognostic  information  provided  by  the  GRACE
RS.  However,  given  the  high  prevalence  of  general  and
abdominal  obesity  observed  in  the  study  population,  clar-
ification  of  obesity-related  risk  is  of  major  importance  and
should  be  reassessed  in  further  research.
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